Regulatory procedures for generic medication approval are crucial to guaranteeing the availability of safe, effective, and inexpensive medicines while preserving strong public health safeguards. This research compares the regulatory requirements for generic drugs in Myanmar, Malaysia, Madagascar, and India, with an emphasis on approval procedures, dossier forms, and compliance expectations. The key regulatory parameters analyzed include governing authorities, legal frameworks, dossier formats, submission systems, Good Manufacturing Practice (GMP) certification, bioequivalence (BE) requirements, stability data, local representation, review timelines, and post-marketing surveillance obligations. Myanmar and Malaysia generally follow the ASEAN Common Technical Dossier (ACTD), which reflects regional regulatory harmonization attempts, whereas India uses the CDSCO SUGAM portal to submit an Abbreviated New Drug Application (ANDA) based on the Common Technical Document. Madagascar uses a national regulatory approach that is consistent with internationally recognized quality, safety, and efficacy requirements. Regardless of procedural differences across jurisdictions, all four regulatory systems priorities proof of pharmaceutical quality, therapeutic equivalency, and manufacturing conformity. The assessment reveals both convergence and variation among national regulatory regimes, as well as potential obstacles in dossier preparation and approval timescales for pharmaceutical businesses. Regulatory affairs experts must have a thorough awareness of these regulatory variances in order to optimize submission strategies, assure compliance, and allow fast market entry for generic pharmaceuticals in varied regulatory settings.